Boom expected in global COVID-19 drug associated APIs market
Market set to grow as companies face fewer operational restrictions and COVID-19 drug development continues at pace
The global market for active pharmaceutical ingredients (APIs) used in the manufacturing of COVID-19 drugs is expected to boom this year, according to a new report on ResearchAndMarkets.
The market is forecast to grow from $5.55 billion in 2021 to $5.99 billion in 2022 at a compound annual growth rate of 7.9%. It is expected to reach $7.55 billion in 2026.
The report’s authors say this growth is largely due to a global relaxation of COVID-19 restrictions, allowing companies to resume operations without the challenges posed by social distancing and remote working requirements. The market was also stunted by disruptions to medical product supply chains during the pandemic, exacerbated by export restrictions implemented in some countries. Now that companies are recovering, the market is expected to surge.
The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals and others. The different types of drugs include generic and branded and involve various business modes such as captive API (produced internally by pharma companies) and merchant API (produced by third-party providers).
Currently North America is the largest region in the COVID-19 drug-associated APIs market, but the Middle East is earmarked to become the fastest growing region in the coming years.
Key players in the market include Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt, Sandoz Srl, Lupin Limited, Aurobindo Pharma, Shanghai Shyndec Pharmaceutical (Haimen) and Yatai Pharma.
They are now faced with the challenge of ensuring adequate plant and production capacity to meet the increasing demand. Some have already expanded their operations, with Alembic Pharmaceuticals ramping up production of azithromycin in 2020 and FUJIFILM announcing the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance